Exploring Synergistic Anti-Psoriatic Potential of Bioactive Compounds Tyrosol and Farnesol through In-Silico and In Vitro Approaches.

INTRODUCTION

Psoriasis is a chronic inflammatory skin disease affected by genetic, immune, and environmental factors. The purpose of the study was to examine the anti-psoriatic properties of Tyrosol and Farnesol against proteins associated with psoriasis, as well as their antioxidant properties.

INTRODUCTION

Psoriasis is a chronic inflammatory skin disease affected by genetic, immune, and environmental factors. The purpose of the study was to examine the anti-psoriatic properties of Tyrosol and Farnesol against proteins associated with psoriasis, as well as their antioxidant properties.

MATERIALS AND

METHODS

A molecular docking simulation (AutoDock) was performed to determine the potential binding between Tyrosol and Farnesol to important targets associated with psoriasis (IL-36, IRAK4, ROR, PDE4D, cPLA2, and RIPK1). DPPH, nitric oxide, and hydrogen peroxide scavenging assays were conducted to determine the antioxidant actions.

RESULTS

Farnesol and Tyrosol competed strongly for binding to RORγt and IRAK4, respectively, and to cPLA2. Both compounds showed significant antioxidant activity, and their combination exhibited enhanced free radical scavenging activity.

DISCUSSION: Interactions and molecular behavior of the compounds, as well as in vitro results, indicate the relevance of the compounds in regulating key inflammatory and oxidative pathways in psoriasis.

CONCLUSION

Tyrosol and Farnesol, especially in combination, are potentially therapeutic agents for the management of psoriasis due to their anti-inflammatory and antioxidant effects.